Active Recombinant Rat RAB5A, Member RAS Oncogene Family

• Cat.No.: Rab5a-1115R

Specification

• Cat. No.: Rab5a-1115R
• Description: Rab5A is a small GTPase that belongs to the Ras superfamily. Rab proteins play an important role in various aspects of membrane traffic, including cargo selection, vesicle budding, vesicle motility, tethering, docking, and fusion. The small Rab5A GTPase is localized to plasma membrane, clathrin coated vesicles, caveosomes and early endosomes. Rab5 is a key regulator of the early endocytic pathway and plays a role in early endosome fusion and caveolar vesicle targeting to early endosomes. Furtermore it is also implicated in EGF receptor activation and apoptotic cell engulfment.
• Source: E. coli.
• Usage: For in vitro use only.
• Form: Liquid. Supplied in 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 10 mM MgCl2, 10 μM GDP and 2 mM mercaptoethanol.
• Activity: 100 pmol of protein can bind > 80 pmol of GDP.
• Purity: ≥ 90% by SDS-PAGE.
• Storage: Quality guaranteed for 12 months. Store at -80℃. Avoid freeze / thaw cycles.

Gene Information

• Gene Name: Rab5a RAB5A, member RAS oncogene family [ Rattus norvegicus ]
• Synonyms: Rab5a; RAB5A, member RAS oncogene family
• Gene ID: 64633
• mRNA Refseq: NM_022692
• Protein Refseq: NP_073183
• UniProt ID: O88565
• Chromosome Location: 9q11
• Pathway: Endocytosis; Amyotrophic lateral sclerosis (ALS)
• Function: GTP binding; GTPase activity; nucleotide binding; protein binding; GDP-dissociation inhibitor binding; guanyl nucleotide binding

Reviews

09/12/2021

If researchers require specific variants or modifications of RAB5A protein, the manufacturer can work with them to provide customized products tailored to their needs.

04/11/2020

Their expertise can help troubleshoot problems, suggest alternative approaches, or provide recommendations for optimizing experimental protocols.

06/17/2018

This level of support saves researchers time and resources, enabling them to focus on the scientific aspects of their work and accelerate the overall progress of their studies.

Q&As

Can targeting RAB5A be a therapeutic approach in cancer treatment?

Research suggests that modulating RAB5A activity may be a viable therapeutic strategy in cancer treatment.

How is RAB5A implicated in clinical applications?

RAB5A is associated with various cellular processes, and its dysregulation has been linked to several diseases.

How does RAB5A contribute to neurodegenerative diseases?

RAB5A dysfunction has been implicated in neurodegenerative diseases, affecting vesicle trafficking and cellular homeostasis in neurons.

Are there diagnostic implications of RAB5A in cancer?

Yes, altered levels of RAB5A expression can serve as potential diagnostic markers for certain cancers.

Are there ongoing clinical trials targeting RAB5A in neurodegenerative diseases?

Some clinical trials are exploring interventions targeting RAB5A to assess their potential in managing neurodegenerative conditions.